Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
出版年份 2014 全文链接
标题
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
作者
关键词
-
出版物
NEURO-ONCOLOGY
Volume 16, Issue 10, Pages 1408-1416
出版商
Oxford University Press (OUP)
发表日期
2014-05-07
DOI
10.1093/neuonc/nou059
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
- (2013) David T W Jones et al. NATURE GENETICS
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
- (2013) NATURE GENETICS
- Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy
- (2013) Thomas Botton et al. Pigment Cell & Melanoma Research
- Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
- (2013) A. J. Sievert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
- (2012) B. C. Widemann et al. CLINICAL CANCER RESEARCH
- Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib
- (2012) Carlo Spirli et al. HEPATOLOGY
- Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
- (2012) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
- (2012) Joann L. Ater et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas
- (2012) Eugene I. Hwang et al. PEDIATRIC BLOOD & CANCER
- Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas
- (2012) AeRang Kim et al. PEDIATRIC BLOOD & CANCER
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice
- (2011) Jan Gronych et al. JOURNAL OF CLINICAL INVESTIGATION
- BRAFAlterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549
- (2011) Alex Lin et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging
- (2011) Jianqiang Wu et al. PEDIATRIC BLOOD & CANCER
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
- (2010) Keith T. Flaherty et al. CANCER BIOLOGY & THERAPY
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma
- (2009) Andrey Korshunov et al. ACTA NEUROPATHOLOGICA
- Gliomas in patients with neurofibromatosis type 1
- (2009) Anne C Albers et al. Expert Review of Neurotherapeutics
- Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy
- (2009) N. T. Ihle et al. MOLECULAR CANCER THERAPEUTICS
- Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan
- (2009) Roger J. Packer et al. PEDIATRIC BLOOD & CANCER
- Dermatologic symptoms associated with the multikinase inhibitor sorafenib
- (2008) Caroline Robert et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now